Sai Parenteral's Limited

BSE: 544742 NSE: SAIPARENT
Sai Parenteral's Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U24231TG2001PLC036043 Incorporated 12 January 2001 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: SAIPARENT · BSE: 544742 Public Limited Company pharma
Data last updated
Market Cap
₹2,236 Cr
SAIPARENT · NSE
Share Price
₹505.95
-0.03% today
Revenue
₹381 Cr
FY 2025-26 · +133.6% YoY
EBITDA
₹38.77 Cr
Margin 10.2%
Net Profit
₹14.27 Cr
FY 2025-26 · -1.0% YoY
P/E (TTM)
89.7x
P/B 10.9x
ROE
4.9%
ROCE 4.8%
Debt / Equity
0.96
Interest cover 84.4x

About Sai Parenteral's Limited

Data last updated:

Sai Parenteral's Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 January 2001 and has been in existence for over 25 years.

Its director Anil Kumar Karusala and family are #1,608 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24231TG2001PLC036043. Its GSTIN is 36AAFCS3053H1ZF (Telangana). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 544742 and NSE: SAIPARENT.

The company has an authorised share capital of ₹25.76 Cr and a paid-up capital of ₹22.09 Cr. It was formerly known as Sai Parenteral'S Private Limited. It is led by directors including Anil Kumar Karusala (Managing Director) and Vijitha Gorrepati (Whole-Time Director).

Its last annual general meeting (AGM) was held on 27 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Hyderabad, Telangana.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹381 Cr, a growth of 133.6% compared to the previous year. For the same year it recorded a net profit of ₹14.27 Cr (net margin 3.7%) and EBITDA of ₹38.77 Cr (EBITDA margin 10.2%). The net worth stands at ₹490.77 Cr (up 423.9% YoY). Total assets are valued at ₹1,094.51 Cr (up 475.4% YoY).

The company has about 274 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: SAI Parenterals. As per MCA filings, the company has open charges of ₹213.36 Cr and satisfied charges of ₹121.89 Cr on record. Court records list 12 cases involving the company, including 6 filed by the company and 6 filed against it; 9 cases are pending. The company has 31 deals on record (19 secondary share transfers, 8 funding rounds, 3 market trades), with disclosed funding of ₹165.67 Cr; the latest was in April 2026.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website saiparenterals.com.

Company details

CIN U24231TG2001PLC036043
Registration Number 036043
Incorporation Date 12 January 2001
ROC Hyderabad
Listing Status Listed - Listed on NSE (SAIPARENT); Listed on BSE (544742)
Company Status Active
Date of Last AGM 27 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Sai Parenteral's has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24231TG2001PLC036043, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24231TG2001PLC036043Current
U24231TG2001PTC036043Previous
U24231AP2001PTC036043Previous
Key People
Anil Kumar Karusala Managing Director Vijitha Gorrepati Whole-Time Director Kalidindi Venkateswara Raju Director

Recognitions & Rankings of Sai Parenteral's

Contact details

Sai Parenteral's Limited's registered office is in Hyderabad, Telangana. Its website is saiparenterals.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    saiparenterals.com
  • Registered Address
    Plot No 39 5th Floor, Lavanya Arcade Jayabheri Enclave Gachibowli, Hyderabad, Telangana, India – 500032
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Sai Parenteral's Limited, buy the company report.

Comprehensive company report
Sai Parenteral's Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Sai Parenteral's operates one associated brand: SAI Parenterals. Each brand links to its own profile.

BrandDescriptionWebsite
SAI Parenterals
Parenteral products including sterile injections and pharmaceutical services are provided.saiparenterals.com

Business activity

The main business activity of Sai Parenteral's is manufacturing. In detail, this covers manufacture of chemicals and chemical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing20Manufacture of chemicals and chemical products

To see the full business activity and turnover split of Sai Parenteral's Limited, buy the company report.

Financials of Sai Parenteral's Limited

FY 2025-26 filings available

Sai Parenteral's Limited reported revenue of ₹381 Cr (up 133.6% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹381 Cr
+133.6% YoY
EBITDA
₹38.77 Cr
-1.5% YoY
Profit After Tax
₹14.27 Cr
-1.0% YoY
Net Worth
₹491 Cr
+423.9% YoY
Total Assets
₹1,095 Cr
+475.4% YoY
Total Debt
₹469 Cr
+398.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue38116315496.80
Revenue growth+133.6%+6.1%+58.8%-
EBITDA38.7739.3831.6918.53
EBITDA margin+10.2%+24.1%+20.6%+19.1%
Profit before tax11.9319.9412.577.24
Net profit14.2714.428.434.36
Net profit margin+3.8%+8.8%+5.5%+4.5%
EPS (₹)3.235.436.356.12
Balance sheet
Total assets1,095190195100
Net worth49193.6774.5531.49
Total debt46993.9611968.55
Cash & bank4172.094.380.17
Net working capital49211811548.21
Cash flow
Cash from operations93.0533.15(29.76)(12.80)
Cash from investing(274)0.44(46.32)(19.03)
Cash from financing596(35.88)78.5723.98
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue19517919896.1553.5333.39
Revenue growth (YoY)+264.1%+435.1%----
Other income3.723.742.883.131.341.17
EBITDA40.2423.5226.09(3.56)11.424.74
EBITDA margin+20.6%+13.2%+13.2%-3.7%+21.3%+14.2%
Depreciation25.098.118.185.791.441.45
Interest8.989.368.405.412.172.46
Profit before tax9.899.7912.39(11.63)9.152.00
Tax(0.62)1.86(0.76)(4.96)2.800.59
Net profit10.517.9313.15(6.67)6.351.41
EPS (₹)2.381.794.02(2.22)34.410.11
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Income statement
Revenue16612711496.80
Revenue growth+31.1%+11.1%+17.7%-
EBITDA28.4826.8621.4817.67
EBITDA margin+17.2%+21.2%+18.9%+18.3%
Profit before tax18.7714.3810.227.28
Net profit16.7810.297.204.56
Net profit margin+10.1%+8.1%+6.3%+4.7%
EPS (₹)3.803.865.416.43
Balance sheet
Total assets622163149100
Net worth48791.2278.0831.48
Total debt13371.7971.1568.55
Cash & bank4101.101.381.91
Net working capital40578.9075.7852.00
Cash flow
Cash from operations11218.68(4.43)(20.83)
Cash from investing(136)(13.16)(31.97)(17.26)
Cash from financing433(5.81)35.8830.23
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue52.9152.7856.7938.4847.7819.20
Revenue growth (YoY)+10.7%+174.9%----
Other income3.593.410.120.750.631.24
Total expenses43.8039.4343.5734.5037.4316.17
EBITDA9.1113.3513.223.9810.353.03
EBITDA margin+17.2%+25.3%+23.3%+10.3%+21.7%+15.8%
Depreciation1.521.361.531.601.341.32
Interest2.493.573.422.121.471.76
Profit before tax8.6911.838.391.018.171.19
Tax2.212.95(1.55)0.642.530.36

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 11 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue19517919896.1553.5333.39
Revenue growth (YoY)+264.1%+435.1%----
Other income3.723.742.883.131.341.17
EBITDA40.2423.5226.09(3.56)11.424.74
EBITDA margin+20.6%+13.2%+13.2%-3.7%+21.3%+14.2%
Depreciation25.098.118.185.791.441.45
Interest8.989.368.405.412.172.46
Profit before tax9.899.7912.39(11.63)9.152.00
Tax(0.62)1.86(0.76)(4.96)2.800.59
Net profit10.517.9313.15(6.67)6.351.41
EPS (₹)2.381.794.02(2.22)34.410.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue38116315496.80
Revenue growth+133.6%+6.1%+58.8%-
Other income8.520.671.420.23
Total expenses34212412278.27
Employee cost29.2813.0912.648.92
EBITDA38.7739.3831.6918.53
EBITDA margin+10.2%+24.1%+20.6%+19.1%
Depreciation16.858.209.425.79
Interest18.5111.9111.125.73
Profit before tax11.9319.9412.577.24
Tax(2.34)5.494.142.88
Net profit14.2714.428.434.36
Net profit margin+3.8%+8.8%+5.5%+4.5%
EPS (₹)3.235.436.356.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital22.0913.3113.257.15
Reserves & surplus46980.3661.3024.34
Shareholders' funds (net worth)49193.6774.5531.49
Minority interest4.352.111.860.00
Secured loans28487.3611468.00
Unsecured loans1856.604.770.55
Total debt46993.9611968.55
Total liabilities1,095190195100
Assets
Gross block43279.5099.3355.08
Net block36453.2070.0144.47
Capital work in progress2120.500.001.60
Investments0.000.000.000.00
Inventories17251.0837.2113.19
Sundry debtors18112712761.21
Cash & bank balances4172.094.380.17
Loans & advances52.1720.1918.697.37
Total current assets82220018781.94
Total current liabilities33082.1672.7133.73
Net working capital49211811548.21
Total assets1,095190195100
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash2.094.381.909.75
Net cash from operating activities93.0533.15(29.76)(12.80)
Net cash from investing activities(274)0.44(46.32)(19.03)
Net cash from financing activities596(35.88)78.5723.98
Net change in cash415(2.30)2.48(7.85)
Closing cash4172.094.380.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+133.6%+6.1%+58.8%-
EBITDA growth-1.6%+24.3%+71.0%-
PBT growth-40.2%+58.6%+73.6%+9997.0%
Net income growth-1.0%+71.1%+93.4%-
Revenue CAGR (3Y)+57.9%---
EBITDA CAGR (3Y)+27.9%---
Profitability & leverage
Net income margin+3.8%+8.9%+5.5%+4.5%
Return on capital employed+4.8%+16.7%+16.1%+13.0%
Return on net worth+4.9%+17.2%+15.9%+13.9%
Debt / equity0.961.261.772.18
Long-term debt / equity0.420.380.741.06
Interest cover84.4438.2049.9344.98
Efficiency & per share
Fixed asset turnover1.491.821.991.76
Inventory turnover3.423.696.107.34
Debtors turnover2.481.291.631.58
EPS (₹)3.235.436.356.12
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)111.0835.1956.2744.03
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue52.9152.7856.7938.4847.7819.20
Revenue growth (YoY)+10.7%+174.9%----
Other income3.593.410.120.750.631.24
Total expenses43.8039.4343.5734.5037.4316.17
EBITDA9.1113.3513.223.9810.353.03
EBITDA margin+17.2%+25.3%+23.3%+10.3%+21.7%+15.8%
Depreciation1.521.361.531.601.341.32
Interest2.493.573.422.121.471.76
Profit before tax8.6911.838.391.018.171.19
Tax2.212.95(1.55)0.642.530.36
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Revenue16612711496.80
Revenue growth+31.1%+11.1%+17.7%-
Other income4.840.321.090.21
Total expenses13799.7292.4179.13
Employee cost14.3010.9210.318.92
EBITDA28.4826.8621.4817.67
EBITDA margin+17.2%+21.2%+18.9%+18.3%
Depreciation5.785.496.185.79
Interest8.777.316.174.81
Profit before tax18.7714.3810.227.28
Tax1.994.093.042.67
Net profit16.7810.297.204.56
Net profit margin+10.1%+8.1%+6.3%+4.7%
EPS (₹)3.803.865.416.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Equity & liabilities
Share capital22.0913.3113.257.15
Reserves & surplus46577.9164.8324.33
Shareholders' funds (net worth)48791.2278.0831.48
Secured loans0.000.0069.3568.00
Unsecured loans13371.791.800.55
Total debt13371.7971.1568.55
Total liabilities622163149100
Assets
Gross block70.7862.1858.1755.08
Net block42.7239.9041.3844.47
Capital work in progress1.090.500.001.60
Investments15828.3928.390.00
Inventories59.5026.1918.9213.19
Sundry debtors81.2286.4984.7861.21
Cash & bank balances4101.101.381.91
Loans & advances35.9316.6615.399.42
Total current assets58713012085.73
Total current liabilities18251.5444.6933.73
Net working capital40578.9075.7852.00
Total assets622163149100
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Opening cash1.101.381.919.76
Net cash from operating activities11218.68(4.43)(20.83)
Net cash from investing activities(136)(13.16)(31.97)(17.26)
Net cash from financing activities433(5.81)35.8830.23
Net change in cash409(0.29)(0.52)(7.85)
Closing cash4101.101.381.91
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23
Growth
Sales growth+31.1%+11.1%+17.7%-
EBITDA growth+6.0%+25.1%+21.6%-
PBT growth+30.4%+40.8%+40.4%+9997.0%
Net income growth+63.1%+42.9%+57.9%-
Revenue CAGR (3Y)+18.8%---
EBITDA CAGR (3Y)+17.3%---
Profitability & leverage
Net income margin+10.3%+8.3%+6.3%+4.8%
Return on capital employed+7.0%+13.9%+13.1%+12.1%
Return on net worth+5.8%+12.1%+13.1%+14.6%
Debt / equity0.350.841.282.18
Long-term debt / equity0.090.180.400.81
Interest cover38.6334.1940.3340.49
Efficiency & per share
Fixed asset turnover2.442.072.011.76
Inventory turnover3.795.517.097.34
Debtors turnover1.931.451.561.58
EPS (₹)3.803.865.416.43
Dividend per share (₹)0.000.000.000.00
Book value per share (₹)110.2334.2758.9444.02

To see the full year-wise statements and ratios of Sai Parenteral's Limited, buy the company report.

Board of directors of Sai Parenteral's Limited

Sai Parenteral's has 6 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Kalidindi Venkateswara Raju
Also directs: Scripture Meditech Private Limited, Narayana Infra Projects India Limited, Sri Ganesh Satya Sai Finance Agencies Private Limited and 1 more
Director12 Nov 20242 Years 0 MonthsCurrent
Bhagyashri Dharmasa Zad
Also directs: Revat Laboratories Private Limited, Ecoboard Industries Limited
Director01 Jan 20242 Years 10 MonthsCurrent
Aruna Karusala
Also directs: Revat Laboratories Private Limited
Director16 Aug 201610 Years 2 MonthsCurrent
Anil Kumar Karusala
Also directs: Revat Laboratories Private Limited, Aanandi Hotels & Resorts Private Limited, SP Analytics Private Limited
Managing Director19 Nov 20214 Years 11 MonthsCurrent
Seeta Ram Anjaneyulu GorantlaDirector01 Jan 20242 Years 10 MonthsCurrent
Vijitha Gorrepati
Also directs: Revat Laboratories Private Limited, SP Analytics Private Limited, Phyto Chem (India) Limited
Whole-Time Director16 Aug 201610 Years 2 MonthsCurrent
View all directors

Auditor

Sai Parenteral's Limited is audited by R. KABRA & CO. LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
R. KABRA & CO. LLPFY 2025104502W/W100721

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 51.20%, foreign institutional investors hold 4.00%, domestic institutional investors hold 8.60% and retail and other public shareholders hold 36.30%.

Promoters: 51.20%DII (Domestic Institutional): 8.60%FII (Foreign Institutional): 4.00%Retail & Others: 36.30%
Sep 2026
QUARTER
51.20% Promoters
8.60% DII (Domestic Institutional)
4.00% FII (Foreign Institutional)
36.30% Retail & Others
Promoter holding - history
Now 51.20% · Sep 2026High 51.20% · Mar 2026Low 51.20% · Mar 2026
50%50.8%51.5%52.3%53%Mar 2026Jun 2026Sep 2026Mar 2026: 51.20%Jun 2026: 51.20%Sep 2026: 51.20%51.20%51.20%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026
Promoters51.20%51.20%51.20%
Public48.80%48.80%48.80%

Charges & borrowings

Open charges
₹213.36 Cr
Satisfied charges
₹121.89 Cr
Breakdown by lending institutions
Others₹105.51 Cr
Axis Bank Limited₹61.00 Cr
The Hongkong and Shanghai Banking Corporation Limited₹24.25 Cr
Hdfc Bank Limited₹20.00 Cr
Sidbi₹2.60 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
17 Dec 2025101210350Others₹38 CrOpen
11 Dec 2025101210375Axis Bank Limited₹61 CrOpen
08 Dec 2025101206434The Hongkong and Shanghai Banking Corporation Limited₹1.25 CrOpen
29 Aug 2025101149137Others₹20 CrOpen
30 Oct 2024101007545Others₹47.51 CrOpen

To see the full charge records of Sai Parenteral's Limited, buy the company report.

Total charge records: 39 View all charges

Deals & funding

Sai Parenteral's Limited has 31 deals on record (19 secondary share transfers, 8 funding rounds, 3 market trades), with disclosed funding of ₹165.67 Cr; the latest was in April 2026.

Total deals
31
Secondary share transfers
19
Funding rounds
8
Market trades
3
IPO
1
Disclosed funding
₹165.67 Cr

Deals on record (5 of 31)

WhenDealAmountParties
Sep 2025Secondary share transferUndisclosedBuyer: Agilis Partners LLP , an individual
Seller: an individual
Aug 2025Funding round₹46.5 CrInvestors: Agilis Partners LLP , Gruhas, Smartgo Prop Llp, an individual
Mar 2025Secondary share transferUndisclosedBuyer: 4 individuals
Seller: Magnifiq Securities Private Limited , 3 individuals
Feb 2024Funding round₹12.02 CrInvestors: Vikasa India Eif I Fund, Ideas and Journeys Private Limited , 2 individuals
Jul 2023Secondary share transferUndisclosedBuyer: Magnifiq Securities Private Limited
Seller: an individual

To see the full deal history of Sai Parenteral's Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Sai Parenteral's Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Sai Parenteral's Limited has a workforce of 274 employees on its EPFO records as of Mar 2026, across 1 active EPFO establishment.

Employee count
274
Active EPFO establishments
1
Employee growth
8.3%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2025-26274
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Sai Parenteral's Limited, buy the company report.

GST

Sai Parenteral's has 2 GST registrations: 1 active and 1 cancelled or inactive.

Total GSTINs
2
Active
1
Cancelled / inactive
1
GSTINStateStatusRegistered on
36AAFCS3053H1ZFTelanganaActive01 Jul 2017

To see the full GST registrations and return filing status of Sai Parenteral's Limited, buy the company report.

Recent activity

Sai Parenteral's Limited has 13 board changes on record since 2010: 6 appointments and 7 cessations. The latest: Kalidindi Venkateswara Raju was appointed as Director on 12 Nov 2024.

Filing
Sai Parenteral'S Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
A charge with Others amounted to Rs. 38.00 Cr with Charge ID 101210350 was registered on 17 Dec 2025.
Charges
A charge with Axis Bank Limited amounted to Rs. 61.00 Cr with Charge ID 101210375 was registered on 11 Dec 2025.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 1.25 Cr with Charge ID 101206434 was registered on 08 Dec 2025.
Charges
A charge with Others of Rs. 20.00 Cr registered on 29 Aug 2025 with Charge ID 101149137 was modified on 03 Oct 2025.
AGM
Sai Parenteral'S Limited last Annual general meeting of members was held on 27 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 20.00 Cr with Charge ID 101149137 was registered on 29 Aug 2025.
Charges
A charge registered on 16 Aug 2021 via Charge ID 100470023 with Sidbi was fully satisfied on 02 Jul 2025.
Charges
A charge registered on 03 Dec 2020 via Charge ID 100393761 with Sidbi was fully satisfied on 02 Jul 2025.
Charges
A charge registered on 21 Jun 2023 via Charge ID 100733480 with Others was fully satisfied on 21 Jan 2025.
Charges
A charge registered on 13 May 2022 via Charge ID 100572364 with Others was fully satisfied on 21 Jan 2025.
Charges
A charge registered on 13 May 2022 via Charge ID 100572372 with Others was fully satisfied on 21 Jan 2025.

88 earlier events are in the company report.

News

SAIPARENT: Q2 CONS NET PROFIT 105M RUPEES VS 63.5M (YOY); Q2 REVENUE 1.95B RUPEES VS 535M (YOY); Q2 EBITDA 403M RUPEES VS 114M (YOY); Q2 EBITDA MARGIN 20.67% VS 21.41% (YOY)
02 Nov 2026 · Exchange Update
SAI Parenterals: Company Finalizes Purchase of 60% Interest in R&D Facility Prathyak Laboratories for ₹15 Crore.
05 Oct 2026 · Exchange Update

Frequently asked questions

Sai Parenteral's is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 January 2001 (25+ years old) and is registered under CIN U24231TG2001PLC036043. Listed on BSE: 544742 and NSE: SAIPARENT.

Sai Parenteral's reported revenue of ₹381 Cr for FY 2025-26 (up 133.6% YoY) based on consolidated financials.

Sai Parenteral's has 6 current directors:

The latest financial statements of Sai Parenteral's on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Sai Parenteral's is 36AAFCS3053H1ZF, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.

The CIN (Corporate Identification Number) of Sai Parenteral's is U24231TG2001PLC036043. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Sai Parenteral's is a listed company as per MCA records. Its shares are listed on both BSE (code: 544742) and NSE (symbol: SAIPARENT).

Sai Parenteral's has 12 court cases on record: 6 filed by the company and 6 filed against it. 9 are pending. Most are in the high courts.

Sai Parenteral's was incorporated on 12 January 2001, making it 25+ years old. It is registered with the Registrar of Companies, Hyderabad.

Sai Parenteral's has 31 deals on record (19 secondary share transfers, 8 funding rounds, 3 market trades), with disclosed funding of ₹165.67 Cr; the latest was in April 2026.